Search

Your search keyword '"Bargiacchi, O"' showing total 4 results
Start Over Author "Bargiacchi, O" Publisher country:gb
4 results on '"Bargiacchi, O"'

1. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?

Author

Bartalucci, C, Baldi, F, Ricci, E, Orofino, G, Menzaghi, B, Ferrara, S, Pellicano', G, Squillace, N, Sarchi, E, Pontali, E, Cenderello, G, Bargiacchi, O, Piccica, M, Carleo, M, Cascio, A, De Socio, G, Bonfanti, P, Di Biagio, A, Bartalucci C., Baldi F., Ricci E., Orofino G., Menzaghi B., Ferrara S., Pellicano' G. F., Squillace N., Sarchi E., Pontali E., Cenderello G., Bargiacchi O., Piccica M., Carleo M. A., Cascio A., De Socio G. V., Bonfanti P., Di Biagio A., Bartalucci, C, Baldi, F, Ricci, E, Orofino, G, Menzaghi, B, Ferrara, S, Pellicano', G, Squillace, N, Sarchi, E, Pontali, E, Cenderello, G, Bargiacchi, O, Piccica, M, Carleo, M, Cascio, A, De Socio, G, Bonfanti, P, Di Biagio, A, Bartalucci C., Baldi F., Ricci E., Orofino G., Menzaghi B., Ferrara S., Pellicano' G. F., Squillace N., Sarchi E., Pontali E., Cenderello G., Bargiacchi O., Piccica M., Carleo M. A., Cascio A., De Socio G. V., Bonfanti P., and Di Biagio A.

Abstract

Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations.

Published
2024

2. TD-1 Efficacy, safety and metabolic changes at 6-months after switch to long-acting injectable CAB/RPV: results from an observational prospective multicenter study

Author

Bartalucci, C, Taramasso, L, Ricci, E, De Vito, A, Squillace, N, Ferrara, S, Pontali, E, Cenderello, G, Pellicanò, G, Sarchi, E, Lagi, F, Salomoni, E, Carleo, M, Bargiacchi, O, Madeddu, G, Cascio, A, Menzaghi, B, De Socio, G, Falasca, K, Bonfanti, P, Di Biagio, A, Pellicanò, GF, Carleo, MA, De Socio, GV, Bartalucci, C, Taramasso, L, Ricci, E, De Vito, A, Squillace, N, Ferrara, S, Pontali, E, Cenderello, G, Pellicanò, G, Sarchi, E, Lagi, F, Salomoni, E, Carleo, M, Bargiacchi, O, Madeddu, G, Cascio, A, Menzaghi, B, De Socio, G, Falasca, K, Bonfanti, P, Di Biagio, A, Pellicanò, GF, Carleo, MA, and De Socio, GV

Published
2024

3. Low level viremia at the beginning and in course of long-acting treatment with injectable cabotegravir and rilpivirine

Author

Taramasso, L, Ricci, E, De Vito, A, Squillace, N, Ferrara, S, Pontali, E, Cenderello, G, Pellicanò, G, Sarchi, E, Lagi, F, Salomoni, E, Carleo, M, Bargiacchi, O, Madeddu, G, Cascio, A, Menzaghi, B, De Socio, G, Falasca, K, Bonfanti, P, Di Biagio, A, Null, N, Pellicanò, GF, Carleo, MA, De Socio, GV, null, null, Taramasso, L, Ricci, E, De Vito, A, Squillace, N, Ferrara, S, Pontali, E, Cenderello, G, Pellicanò, G, Sarchi, E, Lagi, F, Salomoni, E, Carleo, M, Bargiacchi, O, Madeddu, G, Cascio, A, Menzaghi, B, De Socio, G, Falasca, K, Bonfanti, P, Di Biagio, A, Null, N, Pellicanò, GF, Carleo, MA, De Socio, GV, and null, null

Published
2024

4. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens

Author

Maggi, P, Ricci, E, Cicalini, S, Pellicanò, G, Celesia, B, Vichi, F, Cascio, A, Sarchi, E, Orofino, G, Squillace, N, Madeddu, G, De Socio, G, Bargiacchi, O, Molteni, C, Masiello, A, Saracino, A, Menzaghi, B, Falasca, K, Taramasso, L, Di Biagio, A, Bonfanti, P, Maggi, Paolo, Ricci, Elena Delfina, Cicalini, Stefania, Pellicanò, Giovanni Francesco, Celesia, Benedetto Maurizio, Vichi, Francesca, Cascio, Antonio, Sarchi, Eleonora, Orofino, Giancarlo, Squillace, Nicola, Madeddu, Giordano, De Socio, Giuseppe Vittorio, Bargiacchi, Olivia, Molteni, Chiara, Masiello, Addolorata, Saracino, Annalisa, Menzaghi, Barbara, Falasca, Katia, Taramasso, Lucia, Di Biagio, Antonio, Bonfanti, Paolo, Maggi, P, Ricci, E, Cicalini, S, Pellicanò, G, Celesia, B, Vichi, F, Cascio, A, Sarchi, E, Orofino, G, Squillace, N, Madeddu, G, De Socio, G, Bargiacchi, O, Molteni, C, Masiello, A, Saracino, A, Menzaghi, B, Falasca, K, Taramasso, L, Di Biagio, A, Bonfanti, P, Maggi, Paolo, Ricci, Elena Delfina, Cicalini, Stefania, Pellicanò, Giovanni Francesco, Celesia, Benedetto Maurizio, Vichi, Francesca, Cascio, Antonio, Sarchi, Eleonora, Orofino, Giancarlo, Squillace, Nicola, Madeddu, Giordano, De Socio, Giuseppe Vittorio, Bargiacchi, Olivia, Molteni, Chiara, Masiello, Addolorata, Saracino, Annalisa, Menzaghi, Barbara, Falasca, Katia, Taramasso, Lucia, Di Biagio, Antonio, and Bonfanti, Paolo

Abstract

Background: Doravirine (DOR) is a newly approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors (NNRTI), well tolerated and leading to an improved lipid profile in antiretroviral experienced people living with HIV (PLWH). We aimed at evaluating if the lipid-lowering effect is linked to the drug class, using real-life data from the SCOLTA cohort. Methods: We compared the lipid profile modifications in experienced PLWH switching to a DOR-based regimen from rilpivirine or another NNRTI-based regimen or from an integrase strand transferase (INSTI)-based regimen. T0 and T1 were defined as the baseline and 6-month follow-up respectively. Data were collected at baseline and prospectively every six months and changes from baseline were compared using a multivariable linear model. Results: In 107 PLWH, enrolled in the SCOLTA DOR cohort, with undetectable HIV-RNA at baseline, 32.7% switched from RPV-based regimens (DOR1), 29.9% from other NNRTI-including regimens (DOR2) and 37.4% switched from INSTI-including regimens (DOR3). At T1, TC significantly decreased in DOR2 (-15 mg/dL) and DOR3 (-23 mg/dL), and significantly more in DOR3 than in DOR1 (-6 mg/dL) (p = 0.016). HDL-C declined in DOR2 (-2 mg/dL) whereas it increased in DOR1 (+ 3 mg/dL) (p = 0.042) and remained stable in DOR3. LDL-C significantly decreased from baseline in DOR2 (-12 mg/dL) and DOR3 (-22 mg/dL) and was different between DOR1 (-8 mg/dL) and DOR3 (p = 0.022). TC/HDL ratio showed a significant decline in the DOR3 group (-0.45), although similar to DOR1 (-0.23, p = 0.315) and DOR2 (-0.19, p = 0.254). Triglycerides did not noticeably change. ALT significantly decreased in PLWH with a baseline level > 40 UI/mL. Conclusions: PLWH on doravirine treatment showed different trends in blood lipids according to their previous regimen. In PLWH switching from RPV, minimal modifications were seen, whereas in those switching from other NNRTIs and from INSTI-including regimens, w

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results